Seed Treatment Is the Only Input in This Cluster Sold Before the Seed Is Sold

The purchase that is over before the season starts

Every other product in this agricultural input cluster is bought during the season, by a farmer watching a crop, a price and a weather forecast. Seed treatment is bought before any of that exists. In the overwhelming majority of cases it is not bought at all as a separate item — it arrives already on the seed, inside the bag, having been specified by the seed company weeks or months before the grower made the purchase.

That single fact explains more about this market’s behaviour than any agronomic claim made for the products in it. Seed treatment is USD 7.60 billion in 2025, rising to USD 12.55 billion by 2033 at 6.47%, and it is the only input in the chain whose specification is decided upstream of the grower’s own decision-making. Everything else — foliar fungicide, insecticide, nitrogen top-dress, a late herbicide pass — is discretionary at the moment of purchase. This is not.

What that does in a bad year

The 2024–2026 commodity price correction is the natural experiment, and the results are unambiguous. Bayer’s 2025 crop protection and seed mix shows the hierarchy of what a squeezed grower protects: corn seed and traits up 13% on an adjusted basis to EUR 7,149 million, while insecticides fell 12% and fungicides 5%. The seed was bought, and the treatment on it was bought with it, while the spray programme was cut.

The market-level numbers tell the same story. Global crop protection is USD 72.40 billion compounding at 4.12%; seed treatment is a tenth of its size at 6.47%. A bigger, more mature category absorbed the cyclical pain; a smaller one attached to the seed did not have to. That is not because treated seed is a better product than a foliar fungicide. It is because by the time the grower is deciding whether to spend money, the treatment has already been paid for and is sitting in the shed.

Share follows seed share

The bundling has a competitive consequence that is easy to miss and hard to overstate: the four companies that dominate global seed also dominate global seed treatment. Bayer, Syngenta, Corteva through Vylor, and BASF. Every point of seed share a supplier wins carries treatment revenue with it, and the treatment portfolio becomes the place where suppliers differentiate seed offers that are otherwise genetically similar.

The balance sheets show what that combination produces. Bayer Crop Science reported sales of EUR 21,622 million in 2025, up 1.1% on a currency- and portfolio-adjusted basis, with Corn Seed & Traits at EUR 7,149 million doing the heavy lifting. Syngenta Group reported full-year 2025 sales of USD 28.4 billion and EBITDA of USD 4.4 billion, up 13%, with the margin expanding 1.9 percentage points to 15.4%. Those are not the margins of a business selling a commodity spray in the year that commodity sprays were discounted.

Where the bundle is strongest

North America at 34.0% of value on a far smaller share of world seed area is the purest expression of the model: near-universal treatment of corn and soybean seed, and the highest value per treated unit in the world. South America at 24.0% is where intensity is still rising fastest. Asia-Pacific at 19.0% is the largest market by treated area and the most price-sensitive, which is what a market looks like when treatment is a cost to be minimised rather than a specification to be met.

Europe is the exception that proves the rule. At 16.0% it is a smaller share of treatment value than its seed market would imply, and the reason is regulatory rather than commercial: the European Commission’s restriction and subsequent outdoor ban on clothianidin, imidacloprid and thiamethoxam removed the backbone of conventional cereal and oilseed rape dressing, and member states have leaned on emergency authorisations — most visibly for sugar beet — to keep treated seed in the ground. Europe did not stop treating seed. It started treating seed with a narrower, more expensive and more biological toolkit.

Why this is the least cyclical line in the input bill

Three things protect the position. The first is timing: it is committed before the season, so it does not compete with in-season spending for the same cheque. The second is purpose: early-season pest and nematode pressure, including the nematode complexes that have become a leading yield constraint in US and Brazilian soybean, has no effective foliar answer, so cutting the treatment does not defer the problem — it forfeits the crop. The third is regulation, which pushes protection earlier in the season rather than later, as foliar applications face tighter restrictions and residue limits.

The friction is real too. Multiple-component recipes raise compatibility costs, new active substances take five to eight years to register in major jurisdictions, generic competition compresses prices in the simplest dressing categories in India and China, and treated seed crosses borders less readily than untreated seed because a treated lot carries the regulatory status of the product on it. None of that displaces the core advantage. In a chain where every other purchase is a decision, this one arrives already made — and that is worth more in a bad year than it is in a good one.

Sources and editorial references. The sequencing argument in this piece derives from our seed treatment report and the primary sources behind it: US EPA for the registration status of seed-applied actives; and EUR-Lex for the EU seed marketing and plant protection product regimes. Attach rates and treatment value per hectare are as modelled in the report from tier-1 disclosures.